Recent Updates
Recently added Catalysts
MDGL Positive Sentiment

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Monday, August 26, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Madrigal Pharmaceuticals, Inc. will participate in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference, scheduled for September 5, 2024. The company aims to showcase its advancements in developing therapies for nonalcoholic steatohepatitis (NASH). Attendees will be able to access a live webcast of the presentation, with a replay available afterward. This conference highlights Madrigal's commitment to addressing significant medical needs within the liver disease space.
Price reaction · baseline $252.74 (2024-08-23 close) · clean, no other MDGL news in the window
day 0 close
+1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal Pharmaceuticals will showcase its innovations at a prominent conference.
  • The event presents an opportunity for investor engagement and visibility.
  • Madrigal focuses on addressing the high unmet medical need in treating NASH.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
4.2%
average across 7 past catalysts
Cash runway
~45 mo
Minimal dilution risk
Lead asset
Resmetirom
Phase 3 · Non-Alcoholic Fatty Liver Disease

Full Press Release Details

CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 10:45 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Frequently Asked Questions

When is Madrigal Pharmaceuticals presenting at the conference?

Madrigal Pharmaceuticals will present on September 5, 2024, at 10:45 A.M. ET.

How can I access the presentation by Madrigal Pharmaceuticals?

The presentation will be webcast live, accessible via Madrigal’s Investor Relations Events page.

What disease does Madrigal Pharmaceuticals focus on?

Madrigal is developing treatments for nonalcoholic steatohepatitis (NASH).

What is Madrigal's primary medication for NASH?

Madrigal's main drug is Rezdiffra (resmetirom), a liver-directed THR-β agonist.

Is there a replay available for the webcast?

Yes, a replay of the webcast will be available after the event.

ShareAdd on Google
Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals NASH Morgan Stanley biopharmaceuticals healthcare conference
Last updated: Aug 26, 2024

Biotech snapshot

Cash runway
$839M liquidity · $19M/mo burn
~45 mo
Minimal dilution risk
Lead asset
ResmetiromPhase 3
Non-Alcoholic Fatty Liver Disease →

Catalyst track record

+125%
best trade around MDGL's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for MDGL.

See every catalyst's timing & PoA →